401k Plan data: VALUE DRUG COMPANY 401(K) PROFIT-SHARING PLAN plan

VALUE DRUG COMPANY 401(K) PROFIT-SHARING PLAN 401k Plan overview

Plan Name	VALUE DRUG COMPANY 401(K) PROFIT-SHARING PLAN
Plan identification number	001

VALUE DRUG COMPANY 401(K) PROFIT-SHARING PLAN Benefits

401k Plan Type

Defined Contribution Pension

Plan Features/Benefits

Profit-sharing
ERISA section 404(c) Plan - This plan, or any part of it is intended to meet the conditions of 29 CFR 2550.404c-1.
Total participant-directed account plan - Participants have the opportunity to direct the investment of all the assets allocated to their individual accounts, regardless of whether 29 CFR 2550.404c-1 is intended to be met.
Code section 401(k) feature - A cash or deferred arrangement described in Code section 401(k) that is part of a qualified defined contribution plan that provides for an election by employees to defer part of their compensation or receive these amounts in cash.
Code section 401(m) arrangement - Employee contributions are allocated to separate accounts under the plan or employer contributions are based, in whole or in part, on employee deferrals or contribtions to the plan. Not applicable if plan is 401(k) plan with only QNECs and/or QMACs. Also not applicable if Code section 403(b)(1), 403(b)(7) or 408 arrangements/accounts/annuities.
Plan provides for automatic enrollment in plan that has employee contributions deducted from payroll.
Total or partial participant-directed account plan - plan uses default investment account for participants who fail to direct assets in their account.
Master plan - A pension plan that is made available by a sponsor for adoption by employers; that is the subject of a favorable opinion letter; and for which a single funding medium (for example, a trust or custodial account) is established for the joint use of all adopting employers.
Plan sponsor(s) is (are) a member(s) of a controlled group (Code sections 414(b), (c), or (m)).

401k Sponsoring company profile

VALUE DRUG COMPANY has sponsored the creation of one or more 401k plans.

Company Name: VALUE DRUG COMPANY

Employer identification number (EIN): 231179140

NAIC Classification: 424210
NAIC Description: Drugs and Druggists' Sundries Merchant Wholesalers

Form 5500 Filing Information

Submission information for form 5500 for 401k plan VALUE DRUG COMPANY 401(K) PROFIT-SHARING PLAN

Plan id# Filing Submission Date Name of Administrator Date Administrator Signed Name of Company Sponsor Date Sponsor Signed
001 2022-01-01
001 2021-01-01
001 2020-01-01 MORGAN WILLIAMS 2021-10-12 MORGAN WILLIAMS 2021-10-12
001 2019-01-01 MORGAN WILLIAMS 2020-10-11 MORGAN WILLIAMS 2020-10-11
001 2018-01-01 MORGAN WILLIAMS 2019-10-03 MORGAN WILLIAMS 2019-10-03
001 2017-01-01
001 2016-01-01
001 2015-01-01
001 2014-01-01
001 2013-01-01
001 2012-01-01 KEVIN MCKNIGHT KEVIN MCKNIGHT 2013-10-08
001 2011-01-01 KEVIN MCKNIGHT
001 2009-01-01 KEVIN MCKNIGHT
001 2009-01-01 KEVIN MCKNIGHT 2010-10-07

Plan id#	Filing Submission Date	Name of Administrator	Date Administrator Signed	Name of Company Sponsor	Date Sponsor Signed
001	2022-01-01
001	2021-01-01
001	2020-01-01	MORGAN WILLIAMS	2021-10-12	MORGAN WILLIAMS	2021-10-12
001	2019-01-01	MORGAN WILLIAMS	2020-10-11	MORGAN WILLIAMS	2020-10-11
001	2018-01-01	MORGAN WILLIAMS	2019-10-03	MORGAN WILLIAMS	2019-10-03
001	2017-01-01
001	2016-01-01
001	2015-01-01
001	2014-01-01
001	2013-01-01
001	2012-01-01	KEVIN MCKNIGHT		KEVIN MCKNIGHT	2013-10-08
001	2011-01-01	KEVIN MCKNIGHT
001	2009-01-01	KEVIN MCKNIGHT
001	2009-01-01			KEVIN MCKNIGHT	2010-10-07

Plan Statistics for VALUE DRUG COMPANY 401(K) PROFIT-SHARING PLAN

401k plan membership statisitcs for VALUE DRUG COMPANY 401(K) PROFIT-SHARING PLAN

Measure Date Value
2022: VALUE DRUG COMPANY 401(K) PROFIT-SHARING PLAN 2022 401k membership
Total participants, beginning-of-year 2022-01-01 247
Total number of active participants reported on line 7a of the Form 5500 2022-01-01 220
Number of retired or separated participants receiving benefits 2022-01-01 6
Number of other retired or separated participants entitled to future benefits 2022-01-01 31
Total of all active and inactive participants 2022-01-01 257
Number of deceased participants whose beneficiaries are receiving or are entitled to receive benefits 2022-01-01 1
Total participants 2022-01-01 258
Number of participants with account balances 2022-01-01 253
Participants that terminated employment during the plan year with accrued benefits that were less than 100% vested 2022-01-01 18
2021: VALUE DRUG COMPANY 401(K) PROFIT-SHARING PLAN 2021 401k membership
Total participants, beginning-of-year 2021-01-01 255
Total number of active participants reported on line 7a of the Form 5500 2021-01-01 218
Number of retired or separated participants receiving benefits 2021-01-01 3
Number of other retired or separated participants entitled to future benefits 2021-01-01 21
Total of all active and inactive participants 2021-01-01 242
Number of deceased participants whose beneficiaries are receiving or are entitled to receive benefits 2021-01-01 1
Total participants 2021-01-01 243
Number of participants with account balances 2021-01-01 241
Participants that terminated employment during the plan year with accrued benefits that were less than 100% vested 2021-01-01 14
2020: VALUE DRUG COMPANY 401(K) PROFIT-SHARING PLAN 2020 401k membership
Total participants, beginning-of-year 2020-01-01 255
Total number of active participants reported on line 7a of the Form 5500 2020-01-01 223
Number of retired or separated participants receiving benefits 2020-01-01 0
Number of other retired or separated participants entitled to future benefits 2020-01-01 29
Total of all active and inactive participants 2020-01-01 252
Number of deceased participants whose beneficiaries are receiving or are entitled to receive benefits 2020-01-01 0
Total participants 2020-01-01 252
Number of participants with account balances 2020-01-01 251
Participants that terminated employment during the plan year with accrued benefits that were less than 100% vested 2020-01-01 8
2019: VALUE DRUG COMPANY 401(K) PROFIT-SHARING PLAN 2019 401k membership
Total participants, beginning-of-year 2019-01-01 251
Total number of active participants reported on line 7a of the Form 5500 2019-01-01 224
Number of retired or separated participants receiving benefits 2019-01-01 0
Number of other retired or separated participants entitled to future benefits 2019-01-01 28
Total of all active and inactive participants 2019-01-01 252
Number of deceased participants whose beneficiaries are receiving or are entitled to receive benefits 2019-01-01 0
Total participants 2019-01-01 252
Number of participants with account balances 2019-01-01 250
Participants that terminated employment during the plan year with accrued benefits that were less than 100% vested 2019-01-01 13
2018: VALUE DRUG COMPANY 401(K) PROFIT-SHARING PLAN 2018 401k membership
Total participants, beginning-of-year 2018-01-01 232
Total number of active participants reported on line 7a of the Form 5500 2018-01-01 223
Number of retired or separated participants receiving benefits 2018-01-01 0
Number of other retired or separated participants entitled to future benefits 2018-01-01 24
Total of all active and inactive participants 2018-01-01 247
Number of deceased participants whose beneficiaries are receiving or are entitled to receive benefits 2018-01-01 0
Total participants 2018-01-01 247
Number of participants with account balances 2018-01-01 244
Participants that terminated employment during the plan year with accrued benefits that were less than 100% vested 2018-01-01 12
2017: VALUE DRUG COMPANY 401(K) PROFIT-SHARING PLAN 2017 401k membership
Total participants, beginning-of-year 2017-01-01 212
Total number of active participants reported on line 7a of the Form 5500 2017-01-01 210
Number of retired or separated participants receiving benefits 2017-01-01 0
Number of other retired or separated participants entitled to future benefits 2017-01-01 21
Total of all active and inactive participants 2017-01-01 231
Number of deceased participants whose beneficiaries are receiving or are entitled to receive benefits 2017-01-01 0
Total participants 2017-01-01 231
Number of participants with account balances 2017-01-01 227
Participants that terminated employment during the plan year with accrued benefits that were less than 100% vested 2017-01-01 11
2016: VALUE DRUG COMPANY 401(K) PROFIT-SHARING PLAN 2016 401k membership
Total participants, beginning-of-year 2016-01-01 178
Total number of active participants reported on line 7a of the Form 5500 2016-01-01 179
Number of retired or separated participants receiving benefits 2016-01-01 0
Number of other retired or separated participants entitled to future benefits 2016-01-01 23
Total of all active and inactive participants 2016-01-01 202
Number of deceased participants whose beneficiaries are receiving or are entitled to receive benefits 2016-01-01 0
Total participants 2016-01-01 202
Number of participants with account balances 2016-01-01 197
Participants that terminated employment during the plan year with accrued benefits that were less than 100% vested 2016-01-01 3
2015: VALUE DRUG COMPANY 401(K) PROFIT-SHARING PLAN 2015 401k membership
Total participants, beginning-of-year 2015-01-01 154
Total number of active participants reported on line 7a of the Form 5500 2015-01-01 156
Number of retired or separated participants receiving benefits 2015-01-01 0
Number of other retired or separated participants entitled to future benefits 2015-01-01 21
Total of all active and inactive participants 2015-01-01 177
Number of deceased participants whose beneficiaries are receiving or are entitled to receive benefits 2015-01-01 0
Total participants 2015-01-01 177
Number of participants with account balances 2015-01-01 172
Participants that terminated employment during the plan year with accrued benefits that were less than 100% vested 2015-01-01 2
2014: VALUE DRUG COMPANY 401(K) PROFIT-SHARING PLAN 2014 401k membership
Total participants, beginning-of-year 2014-01-01 136
Total number of active participants reported on line 7a of the Form 5500 2014-01-01 143
Number of retired or separated participants receiving benefits 2014-01-01 0
Number of other retired or separated participants entitled to future benefits 2014-01-01 12
Total of all active and inactive participants 2014-01-01 155
Number of deceased participants whose beneficiaries are receiving or are entitled to receive benefits 2014-01-01 0
Total participants 2014-01-01 155
Number of participants with account balances 2014-01-01 143
Participants that terminated employment during the plan year with accrued benefits that were less than 100% vested 2014-01-01 0
2013: VALUE DRUG COMPANY 401(K) PROFIT-SHARING PLAN 2013 401k membership
Total participants, beginning-of-year 2013-01-01 126
Total number of active participants reported on line 7a of the Form 5500 2013-01-01 129
Number of retired or separated participants receiving benefits 2013-01-01 9
Total of all active and inactive participants 2013-01-01 138
Number of deceased participants whose beneficiaries are receiving or are entitled to receive benefits 2013-01-01 0
Total participants 2013-01-01 138
Number of participants with account balances 2013-01-01 126
Participants that terminated employment during the plan year with accrued benefits that were less than 100% vested 2013-01-01 2
2012: VALUE DRUG COMPANY 401(K) PROFIT-SHARING PLAN 2012 401k membership
Total participants, beginning-of-year 2012-01-01 114
Total number of active participants reported on line 7a of the Form 5500 2012-01-01 109
Number of retired or separated participants receiving benefits 2012-01-01 0
Number of other retired or separated participants entitled to future benefits 2012-01-01 5
Total of all active and inactive participants 2012-01-01 114
Number of deceased participants whose beneficiaries are receiving or are entitled to receive benefits 2012-01-01 0
Total participants 2012-01-01 114
Number of participants with account balances 2012-01-01 113
Participants that terminated employment during the plan year with accrued benefits that were less than 100% vested 2012-01-01 0
2011: VALUE DRUG COMPANY 401(K) PROFIT-SHARING PLAN 2011 401k membership
Total participants, beginning-of-year 2011-01-01 112
Total number of active participants reported on line 7a of the Form 5500 2011-01-01 105
Number of retired or separated participants receiving benefits 2011-01-01 0
Number of other retired or separated participants entitled to future benefits 2011-01-01 9
Total of all active and inactive participants 2011-01-01 114
Number of deceased participants whose beneficiaries are receiving or are entitled to receive benefits 2011-01-01 0
Total participants 2011-01-01 114
Number of participants with account balances 2011-01-01 114
Participants that terminated employment during the plan year with accrued benefits that were less than 100% vested 2011-01-01 2
2009: VALUE DRUG COMPANY 401(K) PROFIT-SHARING PLAN 2009 401k membership
Total participants, beginning-of-year 2009-01-01 112
Total number of active participants reported on line 7a of the Form 5500 2009-01-01 102
Number of retired or separated participants receiving benefits 2009-01-01 0
Number of other retired or separated participants entitled to future benefits 2009-01-01 8
Total of all active and inactive participants 2009-01-01 110
Number of deceased participants whose beneficiaries are receiving or are entitled to receive benefits 2009-01-01 0
Total participants 2009-01-01 110
Number of participants with account balances 2009-01-01 110
Participants that terminated employment during the plan year with accrued benefits that were less than 100% vested 2009-01-01 2

Measure	Date	Value
2022: VALUE DRUG COMPANY 401(K) PROFIT-SHARING PLAN 2022 401k membership
Total participants, beginning-of-year	2022-01-01	247
Total number of active participants reported on line 7a of the Form 5500	2022-01-01	220
Number of retired or separated participants receiving benefits	2022-01-01	6
Number of other retired or separated participants entitled to future benefits	2022-01-01	31
Total of all active and inactive participants	2022-01-01	257
Number of deceased participants whose beneficiaries are receiving or are entitled to receive benefits	2022-01-01	1
Total participants	2022-01-01	258
Number of participants with account balances	2022-01-01	253
Participants that terminated employment during the plan year with accrued benefits that were less than 100% vested	2022-01-01	18
2021: VALUE DRUG COMPANY 401(K) PROFIT-SHARING PLAN 2021 401k membership
Total participants, beginning-of-year	2021-01-01	255
Total number of active participants reported on line 7a of the Form 5500	2021-01-01	218
Number of retired or separated participants receiving benefits	2021-01-01	3
Number of other retired or separated participants entitled to future benefits	2021-01-01	21
Total of all active and inactive participants	2021-01-01	242
Number of deceased participants whose beneficiaries are receiving or are entitled to receive benefits	2021-01-01	1
Total participants	2021-01-01	243
Number of participants with account balances	2021-01-01	241
Participants that terminated employment during the plan year with accrued benefits that were less than 100% vested	2021-01-01	14
2020: VALUE DRUG COMPANY 401(K) PROFIT-SHARING PLAN 2020 401k membership
Total participants, beginning-of-year	2020-01-01	255
Total number of active participants reported on line 7a of the Form 5500	2020-01-01	223
Number of retired or separated participants receiving benefits	2020-01-01	0
Number of other retired or separated participants entitled to future benefits	2020-01-01	29
Total of all active and inactive participants	2020-01-01	252
Number of deceased participants whose beneficiaries are receiving or are entitled to receive benefits	2020-01-01	0
Total participants	2020-01-01	252
Number of participants with account balances	2020-01-01	251
Participants that terminated employment during the plan year with accrued benefits that were less than 100% vested	2020-01-01	8
2019: VALUE DRUG COMPANY 401(K) PROFIT-SHARING PLAN 2019 401k membership
Total participants, beginning-of-year	2019-01-01	251
Total number of active participants reported on line 7a of the Form 5500	2019-01-01	224
Number of retired or separated participants receiving benefits	2019-01-01	0
Number of other retired or separated participants entitled to future benefits	2019-01-01	28
Total of all active and inactive participants	2019-01-01	252
Number of deceased participants whose beneficiaries are receiving or are entitled to receive benefits	2019-01-01	0
Total participants	2019-01-01	252
Number of participants with account balances	2019-01-01	250
Participants that terminated employment during the plan year with accrued benefits that were less than 100% vested	2019-01-01	13
2018: VALUE DRUG COMPANY 401(K) PROFIT-SHARING PLAN 2018 401k membership
Total participants, beginning-of-year	2018-01-01	232
Total number of active participants reported on line 7a of the Form 5500	2018-01-01	223
Number of retired or separated participants receiving benefits	2018-01-01	0
Number of other retired or separated participants entitled to future benefits	2018-01-01	24
Total of all active and inactive participants	2018-01-01	247
Number of deceased participants whose beneficiaries are receiving or are entitled to receive benefits	2018-01-01	0
Total participants	2018-01-01	247
Number of participants with account balances	2018-01-01	244
Participants that terminated employment during the plan year with accrued benefits that were less than 100% vested	2018-01-01	12
2017: VALUE DRUG COMPANY 401(K) PROFIT-SHARING PLAN 2017 401k membership
Total participants, beginning-of-year	2017-01-01	212
Total number of active participants reported on line 7a of the Form 5500	2017-01-01	210
Number of retired or separated participants receiving benefits	2017-01-01	0
Number of other retired or separated participants entitled to future benefits	2017-01-01	21
Total of all active and inactive participants	2017-01-01	231
Number of deceased participants whose beneficiaries are receiving or are entitled to receive benefits	2017-01-01	0
Total participants	2017-01-01	231
Number of participants with account balances	2017-01-01	227
Participants that terminated employment during the plan year with accrued benefits that were less than 100% vested	2017-01-01	11
2016: VALUE DRUG COMPANY 401(K) PROFIT-SHARING PLAN 2016 401k membership
Total participants, beginning-of-year	2016-01-01	178
Total number of active participants reported on line 7a of the Form 5500	2016-01-01	179
Number of retired or separated participants receiving benefits	2016-01-01	0
Number of other retired or separated participants entitled to future benefits	2016-01-01	23
Total of all active and inactive participants	2016-01-01	202
Number of deceased participants whose beneficiaries are receiving or are entitled to receive benefits	2016-01-01	0
Total participants	2016-01-01	202
Number of participants with account balances	2016-01-01	197
Participants that terminated employment during the plan year with accrued benefits that were less than 100% vested	2016-01-01	3
2015: VALUE DRUG COMPANY 401(K) PROFIT-SHARING PLAN 2015 401k membership
Total participants, beginning-of-year	2015-01-01	154
Total number of active participants reported on line 7a of the Form 5500	2015-01-01	156
Number of retired or separated participants receiving benefits	2015-01-01	0
Number of other retired or separated participants entitled to future benefits	2015-01-01	21
Total of all active and inactive participants	2015-01-01	177
Number of deceased participants whose beneficiaries are receiving or are entitled to receive benefits	2015-01-01	0
Total participants	2015-01-01	177
Number of participants with account balances	2015-01-01	172
Participants that terminated employment during the plan year with accrued benefits that were less than 100% vested	2015-01-01	2
2014: VALUE DRUG COMPANY 401(K) PROFIT-SHARING PLAN 2014 401k membership
Total participants, beginning-of-year	2014-01-01	136
Total number of active participants reported on line 7a of the Form 5500	2014-01-01	143
Number of retired or separated participants receiving benefits	2014-01-01	0
Number of other retired or separated participants entitled to future benefits	2014-01-01	12
Total of all active and inactive participants	2014-01-01	155
Number of deceased participants whose beneficiaries are receiving or are entitled to receive benefits	2014-01-01	0
Total participants	2014-01-01	155
Number of participants with account balances	2014-01-01	143
Participants that terminated employment during the plan year with accrued benefits that were less than 100% vested	2014-01-01	0
2013: VALUE DRUG COMPANY 401(K) PROFIT-SHARING PLAN 2013 401k membership
Total participants, beginning-of-year	2013-01-01	126
Total number of active participants reported on line 7a of the Form 5500	2013-01-01	129
Number of retired or separated participants receiving benefits	2013-01-01	9
Total of all active and inactive participants	2013-01-01	138
Number of deceased participants whose beneficiaries are receiving or are entitled to receive benefits	2013-01-01	0
Total participants	2013-01-01	138
Number of participants with account balances	2013-01-01	126
Participants that terminated employment during the plan year with accrued benefits that were less than 100% vested	2013-01-01	2
2012: VALUE DRUG COMPANY 401(K) PROFIT-SHARING PLAN 2012 401k membership
Total participants, beginning-of-year	2012-01-01	114
Total number of active participants reported on line 7a of the Form 5500	2012-01-01	109
Number of retired or separated participants receiving benefits	2012-01-01	0
Number of other retired or separated participants entitled to future benefits	2012-01-01	5
Total of all active and inactive participants	2012-01-01	114
Number of deceased participants whose beneficiaries are receiving or are entitled to receive benefits	2012-01-01	0
Total participants	2012-01-01	114
Number of participants with account balances	2012-01-01	113
Participants that terminated employment during the plan year with accrued benefits that were less than 100% vested	2012-01-01	0
2011: VALUE DRUG COMPANY 401(K) PROFIT-SHARING PLAN 2011 401k membership
Total participants, beginning-of-year	2011-01-01	112
Total number of active participants reported on line 7a of the Form 5500	2011-01-01	105
Number of retired or separated participants receiving benefits	2011-01-01	0
Number of other retired or separated participants entitled to future benefits	2011-01-01	9
Total of all active and inactive participants	2011-01-01	114
Number of deceased participants whose beneficiaries are receiving or are entitled to receive benefits	2011-01-01	0
Total participants	2011-01-01	114
Number of participants with account balances	2011-01-01	114
Participants that terminated employment during the plan year with accrued benefits that were less than 100% vested	2011-01-01	2
2009: VALUE DRUG COMPANY 401(K) PROFIT-SHARING PLAN 2009 401k membership
Total participants, beginning-of-year	2009-01-01	112
Total number of active participants reported on line 7a of the Form 5500	2009-01-01	102
Number of retired or separated participants receiving benefits	2009-01-01	0
Number of other retired or separated participants entitled to future benefits	2009-01-01	8
Total of all active and inactive participants	2009-01-01	110
Number of deceased participants whose beneficiaries are receiving or are entitled to receive benefits	2009-01-01	0
Total participants	2009-01-01	110
Number of participants with account balances	2009-01-01	110
Participants that terminated employment during the plan year with accrued benefits that were less than 100% vested	2009-01-01	2

Financial Data on VALUE DRUG COMPANY 401(K) PROFIT-SHARING PLAN

Measure	Date	Value
2022 : VALUE DRUG COMPANY 401(K) PROFIT-SHARING PLAN 2022 401k financial data
Total income from all sources (including contributions)	2022-12-31	$-4,244,648
Total of all expenses incurred	2022-12-31	$1,416,573
Benefit payments and payments to participlants,beneficiaries,insurance carriers and others	2022-12-31	$1,338,239
Expenses. Certain deemed distributions of participant loans	2022-12-31	$0
Total contributions o plan (from employers,participants, others, non cash contrinutions)	2022-12-31	$2,087,965
Value of total assets at end of year	2022-12-31	$35,616,679
Value of total assets at beginning of year	2022-12-31	$41,277,900
Total of administrative expenses incurred including professional, contract, advisory and management fees	2022-12-31	$78,334
Total interest from all sources	2022-12-31	$22,087
Total dividends received (eg from common stock, registered investment company shares)	2022-12-31	$0
Has a resolution to terminate the plan been adopted during the plan year or any prior plan year	2022-12-31	No
Total dividends received from registered investment company shares (eg mutual funds)	2022-12-31	$0
Was this plan covered by a fidelity bond	2022-12-31	Yes
Value of fidelity bond cover	2022-12-31	$500,000
If this is an individual account plan, was there a blackout period	2022-12-31	No
Were there any nonexempt tranactions with any party-in-interest	2022-12-31	No
Contributions received from participants	2022-12-31	$1,321,685
Participant contributions at end of year	2022-12-31	$502,571
Participant contributions at beginning of year	2022-12-31	$390,010
Participant contributions at end of year	2022-12-31	$0
Participant contributions at beginning of year	2022-12-31	$0
Income. Received or receivable in cash from other sources (including rollovers)	2022-12-31	$273
Value of other receiveables (less allowance for doubtful accounts) at end of year	2022-12-31	$0
Value of other receiveables (less allowance for doubtful accounts) at beginning of year	2022-12-31	$0
Administrative expenses (other) incurred	2022-12-31	$78,334
Did the receive any noncash contributions whose value was neither redily determinable on an established market nor set by an independent third party appraiser	2022-12-31	No
Value of net income/loss	2022-12-31	$-5,661,221
Value of net assets at end of year (total assets less liabilities)	2022-12-31	$35,616,679
Value of net assets at beginning of year (total assets less liabilities)	2022-12-31	$41,277,900
Did the plan have a loss casued by fraud or dishonesty (regardless whether reimbursed by fidelity bond)	2022-12-31	No
Were any loans by the plan or fixed income obligations due to the plan in default	2022-12-31	No
Were any leases to which the plan was party in default or uncollectible	2022-12-31	No
Value of interest in registered invesment companies (eg mutual funds) at end of year	2022-12-31	$31,630,027
Value of interest in registered invesment companies (eg mutual funds) at beginning of year	2022-12-31	$38,319,460
Interest on participant loans	2022-12-31	$22,087
Value of interest in common/collective trusts at end of year	2022-12-31	$3,325,276
Value of interest in common/collective trusts at beginning of year	2022-12-31	$2,225,662
Interest earned from interest bearing cash (including money market accounts and certificates of deposit)	2022-12-31	$0
Expenses. Payments to insurance carriers foe the provision of benefits	2022-12-31	$0
Net investment gain/loss from registered investment companies (e.g. mutual funds)	2022-12-31	$-6,354,700
Were any plan transactions or series of transactions in excess of 5% of the current value of the plan assets	2022-12-31	No
Was there a failure to transmit to the plan any participant contributions	2022-12-31	No
Has the plan failed to provide any benefit when due under the plan	2022-12-31	No
Contributions received in cash from employer	2022-12-31	$766,007
Employer contributions (assets) at end of year	2022-12-31	$158,805
Employer contributions (assets) at beginning of year	2022-12-31	$342,768
Benefit payments and payments to provide benefits directly to participlants or beneficiaries including direct rollovers	2022-12-31	$1,338,239
Was the provided the required notice or one of the exceptions to providing the black out period notice applied under 29 CFR 2520.101-3	2022-12-31	No
Did the plan have assets held for investment	2022-12-31	Yes
Did the plan hold any assets whose current value was neither redily determinable on an established market nor set by an independent third party appraiser	2022-12-31	No
Were all the plan assets eitehr distributed to particpants/beneficiaries, transferred to another plan or brought under the control of the PBGC	2022-12-31	No
Opinion of an independent qualified public accountant for this plan	2022-12-31	Unqualified
Accountancy firm name	2022-12-31	YOUNG, OAKES, BROWN & CO., PC
Accountancy firm EIN	2022-12-31	251589048
2021 : VALUE DRUG COMPANY 401(K) PROFIT-SHARING PLAN 2021 401k financial data
Total income from all sources (including contributions)	2021-12-31	$6,710,984
Total of all expenses incurred	2021-12-31	$4,333,368
Benefit payments and payments to participlants,beneficiaries,insurance carriers and others	2021-12-31	$4,246,495
Expenses. Certain deemed distributions of participant loans	2021-12-31	$0
Total contributions o plan (from employers,participants, others, non cash contrinutions)	2021-12-31	$2,125,786
Value of total assets at end of year	2021-12-31	$41,277,900
Value of total assets at beginning of year	2021-12-31	$38,900,284
Total of administrative expenses incurred including professional, contract, advisory and management fees	2021-12-31	$86,873
Total interest from all sources	2021-12-31	$17,891
Total dividends received (eg from common stock, registered investment company shares)	2021-12-31	$0
Has a resolution to terminate the plan been adopted during the plan year or any prior plan year	2021-12-31	No
Total dividends received from registered investment company shares (eg mutual funds)	2021-12-31	$0
Was this plan covered by a fidelity bond	2021-12-31	Yes
Value of fidelity bond cover	2021-12-31	$500,000
If this is an individual account plan, was there a blackout period	2021-12-31	No
Total value of distributions paid in property other than in cash, annuity contracts, or publicly traded employer securities	2021-12-31	$0
Were there any nonexempt tranactions with any party-in-interest	2021-12-31	No
Contributions received from participants	2021-12-31	$1,271,230
Participant contributions at end of year	2021-12-31	$390,010
Participant contributions at beginning of year	2021-12-31	$396,839
Participant contributions at end of year	2021-12-31	$0
Income. Received or receivable in cash from other sources (including rollovers)	2021-12-31	$7,510
Value of other receiveables (less allowance for doubtful accounts) at end of year	2021-12-31	$0
Administrative expenses (other) incurred	2021-12-31	$86,873
Did the receive any noncash contributions whose value was neither redily determinable on an established market nor set by an independent third party appraiser	2021-12-31	No
Value of net income/loss	2021-12-31	$2,377,616
Value of net assets at end of year (total assets less liabilities)	2021-12-31	$41,277,900
Value of net assets at beginning of year (total assets less liabilities)	2021-12-31	$38,900,284
Did the plan have a loss casued by fraud or dishonesty (regardless whether reimbursed by fidelity bond)	2021-12-31	No
Were any loans by the plan or fixed income obligations due to the plan in default	2021-12-31	No
Were any leases to which the plan was party in default or uncollectible	2021-12-31	No
Value of interest in registered invesment companies (eg mutual funds) at end of year	2021-12-31	$38,319,460
Value of interest in registered invesment companies (eg mutual funds) at beginning of year	2021-12-31	$38,263,283
Interest on participant loans	2021-12-31	$17,891
Value of interest in common/collective trusts at end of year	2021-12-31	$2,225,662
Value of interest in common/collective trusts at beginning of year	2021-12-31	$74,207
Interest earned from interest bearing cash (including money market accounts and certificates of deposit)	2021-12-31	$0
Expenses. Payments to insurance carriers foe the provision of benefits	2021-12-31	$0
Net investment gain/loss from registered investment companies (e.g. mutual funds)	2021-12-31	$4,567,307
Were any plan transactions or series of transactions in excess of 5% of the current value of the plan assets	2021-12-31	No
Was there a failure to transmit to the plan any participant contributions	2021-12-31	No
Has the plan failed to provide any benefit when due under the plan	2021-12-31	No
Contributions received in cash from employer	2021-12-31	$847,046
Employer contributions (assets) at end of year	2021-12-31	$342,768
Employer contributions (assets) at beginning of year	2021-12-31	$165,955
Benefit payments and payments to provide benefits directly to participlants or beneficiaries including direct rollovers	2021-12-31	$4,246,495
Did the plan have assets held for investment	2021-12-31	Yes
Did the plan hold any assets whose current value was neither redily determinable on an established market nor set by an independent third party appraiser	2021-12-31	No
Were all the plan assets eitehr distributed to particpants/beneficiaries, transferred to another plan or brought under the control of the PBGC	2021-12-31	No
Opinion of an independent qualified public accountant for this plan	2021-12-31	Unqualified
Accountancy firm name	2021-12-31	YOUNG, OAKES, BROWN & CO., PC
Accountancy firm EIN	2021-12-31	251589048
2020 : VALUE DRUG COMPANY 401(K) PROFIT-SHARING PLAN 2020 401k financial data
Total unrealized appreciation/depreciation of assets	2020-12-31	$0
Total liabilities at end of year (benefit claims payable, operating payabales, acquisition indebtedness and other liabilities)	2020-12-31	$0
Total liabilities at beginning of year (benefit claims payable, operating payabales, acquisition indebtedness and other liabilities)	2020-12-31	$0
Total income from all sources (including contributions)	2020-12-31	$7,455,395
Total loss/gain on sale of assets	2020-12-31	$0
Total of all expenses incurred	2020-12-31	$1,597,411
Benefit payments and payments to participlants,beneficiaries,insurance carriers and others	2020-12-31	$1,588,405
Total contributions o plan (from employers,participants, others, non cash contrinutions)	2020-12-31	$2,643,927
Value of total assets at end of year	2020-12-31	$38,900,284
Value of total assets at beginning of year	2020-12-31	$33,042,300
Total of administrative expenses incurred including professional, contract, advisory and management fees	2020-12-31	$9,006
Total interest from all sources	2020-12-31	$20,336
Total dividends received (eg from common stock, registered investment company shares)	2020-12-31	$0
Has a resolution to terminate the plan been adopted during the plan year or any prior plan year	2020-12-31	No
Was this plan covered by a fidelity bond	2020-12-31	Yes
Value of fidelity bond cover	2020-12-31	$500,000
If this is an individual account plan, was there a blackout period	2020-12-31	Yes
Total value of distributions paid in property other than in cash, annuity contracts, or publicly traded employer securities	2020-12-31	$0
Were there any nonexempt tranactions with any party-in-interest	2020-12-31	No
Contributions received from participants	2020-12-31	$1,281,318
Participant contributions at end of year	2020-12-31	$396,839
Participant contributions at beginning of year	2020-12-31	$446,564
Income. Received or receivable in cash from other sources (including rollovers)	2020-12-31	$5,140
Other income not declared elsewhere	2020-12-31	$4,023
Administrative expenses (other) incurred	2020-12-31	$9,006
Did the receive any noncash contributions whose value was neither redily determinable on an established market nor set by an independent third party appraiser	2020-12-31	No
Value of net income/loss	2020-12-31	$5,857,984
Value of net assets at end of year (total assets less liabilities)	2020-12-31	$38,900,284
Value of net assets at beginning of year (total assets less liabilities)	2020-12-31	$33,042,300
Did the plan have a loss casued by fraud or dishonesty (regardless whether reimbursed by fidelity bond)	2020-12-31	No
Were any loans by the plan or fixed income obligations due to the plan in default	2020-12-31	No
Were any leases to which the plan was party in default or uncollectible	2020-12-31	No
Value of interest in pooled separate accounts at end of year	2020-12-31	$38,263,283
Value of interest in pooled separate accounts at beginning of year	2020-12-31	$31,331,819
Interest on participant loans	2020-12-31	$20,336
Value of interest in common/collective trusts at end of year	2020-12-31	$74,207
Value of interest in common/collective trusts at beginning of year	2020-12-31	$1,263,917
Net investment gain/loss from registered investment companies (e.g. mutual funds)	2020-12-31	$4,786,972
Net investment gain or loss from common/collective trusts	2020-12-31	$137
Were any plan transactions or series of transactions in excess of 5% of the current value of the plan assets	2020-12-31	No
Was there a failure to transmit to the plan any participant contributions	2020-12-31	No
Has the plan failed to provide any benefit when due under the plan	2020-12-31	No
Contributions received in cash from employer	2020-12-31	$1,357,469
Employer contributions (assets) at end of year	2020-12-31	$165,955
Employer contributions (assets) at beginning of year	2020-12-31	$0
Benefit payments and payments to provide benefits directly to participlants or beneficiaries including direct rollovers	2020-12-31	$1,588,405
Was the provided the required notice or one of the exceptions to providing the black out period notice applied under 29 CFR 2520.101-3	2020-12-31	Yes
Did the plan have assets held for investment	2020-12-31	Yes
Did the plan hold any assets whose current value was neither redily determinable on an established market nor set by an independent third party appraiser	2020-12-31	No
Were all the plan assets eitehr distributed to particpants/beneficiaries, transferred to another plan or brought under the control of the PBGC	2020-12-31	No
Opinion of an independent qualified public accountant for this plan	2020-12-31	Disclaimer
Accountancy firm name	2020-12-31	FIORE FEDELI SNYDER CAROTHERS, LLP
Accountancy firm EIN	2020-12-31	202000257
2019 : VALUE DRUG COMPANY 401(K) PROFIT-SHARING PLAN 2019 401k financial data
Total unrealized appreciation/depreciation of assets	2019-12-31	$0
Total liabilities at end of year (benefit claims payable, operating payabales, acquisition indebtedness and other liabilities)	2019-12-31	$0
Total liabilities at beginning of year (benefit claims payable, operating payabales, acquisition indebtedness and other liabilities)	2019-12-31	$0
Total income from all sources (including contributions)	2019-12-31	$8,397,606
Total loss/gain on sale of assets	2019-12-31	$0
Total of all expenses incurred	2019-12-31	$3,138,992
Benefit payments and payments to participlants,beneficiaries,insurance carriers and others	2019-12-31	$3,123,480
Value of total corrective distributions	2019-12-31	$9,606
Total contributions o plan (from employers,participants, others, non cash contrinutions)	2019-12-31	$2,573,190
Value of total assets at end of year	2019-12-31	$33,042,300
Value of total assets at beginning of year	2019-12-31	$27,783,686
Total of administrative expenses incurred including professional, contract, advisory and management fees	2019-12-31	$5,906
Total interest from all sources	2019-12-31	$20,441
Total dividends received (eg from common stock, registered investment company shares)	2019-12-31	$0
Has a resolution to terminate the plan been adopted during the plan year or any prior plan year	2019-12-31	No
Was this plan covered by a fidelity bond	2019-12-31	Yes
Value of fidelity bond cover	2019-12-31	$500,000
If this is an individual account plan, was there a blackout period	2019-12-31	No
Total value of distributions paid in property other than in cash, annuity contracts, or publicly traded employer securities	2019-12-31	$0
Were there any nonexempt tranactions with any party-in-interest	2019-12-31	No
Contributions received from participants	2019-12-31	$1,171,356
Participant contributions at end of year	2019-12-31	$446,564
Participant contributions at beginning of year	2019-12-31	$339,058
Income. Received or receivable in cash from other sources (including rollovers)	2019-12-31	$6,881
Did the receive any noncash contributions whose value was neither redily determinable on an established market nor set by an independent third party appraiser	2019-12-31	No
Value of net income/loss	2019-12-31	$5,258,614
Value of net assets at end of year (total assets less liabilities)	2019-12-31	$33,042,300
Value of net assets at beginning of year (total assets less liabilities)	2019-12-31	$27,783,686
Did the plan have a loss casued by fraud or dishonesty (regardless whether reimbursed by fidelity bond)	2019-12-31	No
Were any loans by the plan or fixed income obligations due to the plan in default	2019-12-31	No
Were any leases to which the plan was party in default or uncollectible	2019-12-31	No
Value of interest in pooled separate accounts at end of year	2019-12-31	$31,331,819
Value of interest in pooled separate accounts at beginning of year	2019-12-31	$25,759,828
Interest on participant loans	2019-12-31	$20,441
Interest earned on other investments	2019-12-31	$0
Value of interest in common/collective trusts at end of year	2019-12-31	$1,263,917
Value of interest in common/collective trusts at beginning of year	2019-12-31	$1,684,800
Net investment gain/loss from pooled separate accounts	2019-12-31	$5,790,433
Net investment gain or loss from common/collective trusts	2019-12-31	$13,542
Were any plan transactions or series of transactions in excess of 5% of the current value of the plan assets	2019-12-31	No
Was there a failure to transmit to the plan any participant contributions	2019-12-31	No
Has the plan failed to provide any benefit when due under the plan	2019-12-31	No
Contributions received in cash from employer	2019-12-31	$1,394,953
Benefit payments and payments to provide benefits directly to participlants or beneficiaries including direct rollovers	2019-12-31	$3,123,480
Contract administrator fees	2019-12-31	$5,906
Did the plan have assets held for investment	2019-12-31	Yes
Did the plan hold any assets whose current value was neither redily determinable on an established market nor set by an independent third party appraiser	2019-12-31	No
Were all the plan assets eitehr distributed to particpants/beneficiaries, transferred to another plan or brought under the control of the PBGC	2019-12-31	No
Accountant perfomed limited scope audit pursuant to 29 CFR 2520.103-8 and/or 103-12(d)	2019-12-31	Yes
Opinion of an independent qualified public accountant for this plan	2019-12-31	Disclaimer
Accountancy firm name	2019-12-31	FIORE FEDELI SNYDER CAROTHERS, LLP
Accountancy firm EIN	2019-12-31	202000257
2018 : VALUE DRUG COMPANY 401(K) PROFIT-SHARING PLAN 2018 401k financial data
Total unrealized appreciation/depreciation of assets	2018-12-31	$0
Total liabilities at end of year (benefit claims payable, operating payabales, acquisition indebtedness and other liabilities)	2018-12-31	$0
Total liabilities at beginning of year (benefit claims payable, operating payabales, acquisition indebtedness and other liabilities)	2018-12-31	$0
Total income from all sources (including contributions)	2018-12-31	$1,204,639
Total loss/gain on sale of assets	2018-12-31	$0
Total of all expenses incurred	2018-12-31	$1,691,219
Benefit payments and payments to participlants,beneficiaries,insurance carriers and others	2018-12-31	$1,687,275
Total contributions o plan (from employers,participants, others, non cash contrinutions)	2018-12-31	$2,643,052
Value of total assets at end of year	2018-12-31	$27,783,686
Value of total assets at beginning of year	2018-12-31	$28,270,266
Total of administrative expenses incurred including professional, contract, advisory and management fees	2018-12-31	$3,944
Total interest from all sources	2018-12-31	$113,842
Total dividends received (eg from common stock, registered investment company shares)	2018-12-31	$0
Has a resolution to terminate the plan been adopted during the plan year or any prior plan year	2018-12-31	No
Was this plan covered by a fidelity bond	2018-12-31	Yes
Value of fidelity bond cover	2018-12-31	$500,000
If this is an individual account plan, was there a blackout period	2018-12-31	No
Total value of distributions paid in property other than in cash, annuity contracts, or publicly traded employer securities	2018-12-31	$0
Were there any nonexempt tranactions with any party-in-interest	2018-12-31	No
Contributions received from participants	2018-12-31	$1,144,160
Participant contributions at end of year	2018-12-31	$339,058
Participant contributions at beginning of year	2018-12-31	$353,223
Income. Received or receivable in cash from other sources (including rollovers)	2018-12-31	$32,022
Did the receive any noncash contributions whose value was neither redily determinable on an established market nor set by an independent third party appraiser	2018-12-31	No
Value of net income/loss	2018-12-31	$-486,580
Value of net assets at end of year (total assets less liabilities)	2018-12-31	$27,783,686
Value of net assets at beginning of year (total assets less liabilities)	2018-12-31	$28,270,266
Did the plan have a loss casued by fraud or dishonesty (regardless whether reimbursed by fidelity bond)	2018-12-31	No
Were any loans by the plan or fixed income obligations due to the plan in default	2018-12-31	No
Were any leases to which the plan was party in default or uncollectible	2018-12-31	No
Value of interest in pooled separate accounts at end of year	2018-12-31	$25,759,828
Value of interest in pooled separate accounts at beginning of year	2018-12-31	$26,554,841
Interest on participant loans	2018-12-31	$16,698
Interest earned on other investments	2018-12-31	$97,144
Value of interest in common/collective trusts at end of year	2018-12-31	$1,684,800
Value of interest in common/collective trusts at beginning of year	2018-12-31	$1,362,202
Net investment gain/loss from pooled separate accounts	2018-12-31	$-1,564,747
Net investment gain or loss from common/collective trusts	2018-12-31	$12,492
Were any plan transactions or series of transactions in excess of 5% of the current value of the plan assets	2018-12-31	No
Was there a failure to transmit to the plan any participant contributions	2018-12-31	No
Has the plan failed to provide any benefit when due under the plan	2018-12-31	No
Contributions received in cash from employer	2018-12-31	$1,466,870
Benefit payments and payments to provide benefits directly to participlants or beneficiaries including direct rollovers	2018-12-31	$1,687,275
Contract administrator fees	2018-12-31	$3,944
Did the plan have assets held for investment	2018-12-31	Yes
Did the plan hold any assets whose current value was neither redily determinable on an established market nor set by an independent third party appraiser	2018-12-31	No
Were all the plan assets eitehr distributed to particpants/beneficiaries, transferred to another plan or brought under the control of the PBGC	2018-12-31	No
Accountant perfomed limited scope audit pursuant to 29 CFR 2520.103-8 and/or 103-12(d)	2018-12-31	Yes
Opinion of an independent qualified public accountant for this plan	2018-12-31	Disclaimer
Accountancy firm name	2018-12-31	FIORE FEDELI SNYDER CAROTHERS, LLP
Accountancy firm EIN	2018-12-31	202000257
2017 : VALUE DRUG COMPANY 401(K) PROFIT-SHARING PLAN 2017 401k financial data
Total unrealized appreciation/depreciation of assets	2017-12-31	$0
Total liabilities at end of year (benefit claims payable, operating payabales, acquisition indebtedness and other liabilities)	2017-12-31	$0
Total liabilities at beginning of year (benefit claims payable, operating payabales, acquisition indebtedness and other liabilities)	2017-12-31	$0
Total income from all sources (including contributions)	2017-12-31	$6,328,949
Total loss/gain on sale of assets	2017-12-31	$0
Total of all expenses incurred	2017-12-31	$1,223,808
Benefit payments and payments to participlants,beneficiaries,insurance carriers and others	2017-12-31	$1,212,974
Expenses. Certain deemed distributions of participant loans	2017-12-31	$6,812
Total contributions o plan (from employers,participants, others, non cash contrinutions)	2017-12-31	$2,467,034
Value of total assets at end of year	2017-12-31	$28,270,266
Value of total assets at beginning of year	2017-12-31	$23,165,125
Total of administrative expenses incurred including professional, contract, advisory and management fees	2017-12-31	$4,022
Total interest from all sources	2017-12-31	$12,989
Total dividends received (eg from common stock, registered investment company shares)	2017-12-31	$0
Has a resolution to terminate the plan been adopted during the plan year or any prior plan year	2017-12-31	No
Was this plan covered by a fidelity bond	2017-12-31	Yes
Value of fidelity bond cover	2017-12-31	$500,000
If this is an individual account plan, was there a blackout period	2017-12-31	No
Total value of distributions paid in property other than in cash, annuity contracts, or publicly traded employer securities	2017-12-31	$0
Were there any nonexempt tranactions with any party-in-interest	2017-12-31	No
Contributions received from participants	2017-12-31	$974,348
Participant contributions at end of year	2017-12-31	$353,223
Participant contributions at beginning of year	2017-12-31	$223,738
Income. Received or receivable in cash from other sources (including rollovers)	2017-12-31	$174,210
Administrative expenses (other) incurred	2017-12-31	$2,950
Did the receive any noncash contributions whose value was neither redily determinable on an established market nor set by an independent third party appraiser	2017-12-31	No
Value of net income/loss	2017-12-31	$5,105,141
Value of net assets at end of year (total assets less liabilities)	2017-12-31	$28,270,266
Value of net assets at beginning of year (total assets less liabilities)	2017-12-31	$23,165,125
Did the plan have a loss casued by fraud or dishonesty (regardless whether reimbursed by fidelity bond)	2017-12-31	No
Were any loans by the plan or fixed income obligations due to the plan in default	2017-12-31	No
Were any leases to which the plan was party in default or uncollectible	2017-12-31	No
Value of interest in pooled separate accounts at end of year	2017-12-31	$26,554,841
Value of interest in pooled separate accounts at beginning of year	2017-12-31	$21,635,410
Interest on participant loans	2017-12-31	$12,989
Value of interest in common/collective trusts at end of year	2017-12-31	$1,362,202
Value of interest in common/collective trusts at beginning of year	2017-12-31	$1,305,977
Net investment gain/loss from pooled separate accounts	2017-12-31	$3,839,762
Net investment gain or loss from common/collective trusts	2017-12-31	$9,164
Were any plan transactions or series of transactions in excess of 5% of the current value of the plan assets	2017-12-31	No
Was there a failure to transmit to the plan any participant contributions	2017-12-31	No
Has the plan failed to provide any benefit when due under the plan	2017-12-31	No
Contributions received in cash from employer	2017-12-31	$1,318,476
Benefit payments and payments to provide benefits directly to participlants or beneficiaries including direct rollovers	2017-12-31	$1,212,974
Contract administrator fees	2017-12-31	$1,072
Did the plan have assets held for investment	2017-12-31	Yes
Did the plan hold any assets whose current value was neither redily determinable on an established market nor set by an independent third party appraiser	2017-12-31	No
Were all the plan assets eitehr distributed to particpants/beneficiaries, transferred to another plan or brought under the control of the PBGC	2017-12-31	No
Accountant perfomed limited scope audit pursuant to 29 CFR 2520.103-8 and/or 103-12(d)	2017-12-31	Yes
Opinion of an independent qualified public accountant for this plan	2017-12-31	Disclaimer
Accountancy firm name	2017-12-31	FIORE FEDELI SNYDER CAROTHERS, LLP
Accountancy firm EIN	2017-12-31	202000257
2016 : VALUE DRUG COMPANY 401(K) PROFIT-SHARING PLAN 2016 401k financial data
Total unrealized appreciation/depreciation of assets	2016-12-31	$0
Total liabilities at end of year (benefit claims payable, operating payabales, acquisition indebtedness and other liabilities)	2016-12-31	$0
Total liabilities at beginning of year (benefit claims payable, operating payabales, acquisition indebtedness and other liabilities)	2016-12-31	$0
Total income from all sources (including contributions)	2016-12-31	$3,479,940
Total loss/gain on sale of assets	2016-12-31	$0
Total of all expenses incurred	2016-12-31	$1,036,351
Benefit payments and payments to participlants,beneficiaries,insurance carriers and others	2016-12-31	$1,034,533
Total contributions o plan (from employers,participants, others, non cash contrinutions)	2016-12-31	$2,021,789
Value of total assets at end of year	2016-12-31	$23,165,125
Value of total assets at beginning of year	2016-12-31	$20,721,536
Total of administrative expenses incurred including professional, contract, advisory and management fees	2016-12-31	$1,818
Total interest from all sources	2016-12-31	$21,028
Total dividends received (eg from common stock, registered investment company shares)	2016-12-31	$1,437,123
Has a resolution to terminate the plan been adopted during the plan year or any prior plan year	2016-12-31	No
Total dividends received from registered investment company shares (eg mutual funds)	2016-12-31	$1,437,123
Was this plan covered by a fidelity bond	2016-12-31	Yes
Value of fidelity bond cover	2016-12-31	$500,000
If this is an individual account plan, was there a blackout period	2016-12-31	No
Were there any nonexempt tranactions with any party-in-interest	2016-12-31	No
Contributions received from participants	2016-12-31	$831,400
Participant contributions at end of year	2016-12-31	$223,738
Participant contributions at beginning of year	2016-12-31	$322,561
Income. Received or receivable in cash from other sources (including rollovers)	2016-12-31	$77,655
Administrative expenses (other) incurred	2016-12-31	$13
Did the receive any noncash contributions whose value was neither redily determinable on an established market nor set by an independent third party appraiser	2016-12-31	No
Value of net income/loss	2016-12-31	$2,443,589
Value of net assets at end of year (total assets less liabilities)	2016-12-31	$23,165,125
Value of net assets at beginning of year (total assets less liabilities)	2016-12-31	$20,721,536
Did the plan have a loss casued by fraud or dishonesty (regardless whether reimbursed by fidelity bond)	2016-12-31	No
Were any loans by the plan or fixed income obligations due to the plan in default	2016-12-31	No
Were any leases to which the plan was party in default or uncollectible	2016-12-31	No
Value of interest in pooled separate accounts at end of year	2016-12-31	$21,635,410
Value of interest in pooled separate accounts at beginning of year	2016-12-31	$19,278,713
Interest on participant loans	2016-12-31	$11,558
Value of interest in common/collective trusts at end of year	2016-12-31	$1,305,977
Value of interest in common/collective trusts at beginning of year	2016-12-31	$1,120,262
Interest earned from interest bearing cash (including money market accounts and certificates of deposit)	2016-12-31	$9,470
Expenses. Payments to insurance carriers foe the provision of benefits	2016-12-31	$5,639
Were any plan transactions or series of transactions in excess of 5% of the current value of the plan assets	2016-12-31	No
Was there a failure to transmit to the plan any participant contributions	2016-12-31	No
Has the plan failed to provide any benefit when due under the plan	2016-12-31	No
Contributions received in cash from employer	2016-12-31	$1,112,734
Benefit payments and payments to provide benefits directly to participlants or beneficiaries including direct rollovers	2016-12-31	$1,028,894
Contract administrator fees	2016-12-31	$1,805
Did the plan have assets held for investment	2016-12-31	Yes
Did the plan hold any assets whose current value was neither redily determinable on an established market nor set by an independent third party appraiser	2016-12-31	No
Were all the plan assets eitehr distributed to particpants/beneficiaries, transferred to another plan or brought under the control of the PBGC	2016-12-31	No
Accountant perfomed limited scope audit pursuant to 29 CFR 2520.103-8 and/or 103-12(d)	2016-12-31	Yes
Opinion of an independent qualified public accountant for this plan	2016-12-31	Disclaimer
Accountancy firm name	2016-12-31	YOUNG, OAKES, BROWN & CO., PC
Accountancy firm EIN	2016-12-31	251589048
2015 : VALUE DRUG COMPANY 401(K) PROFIT-SHARING PLAN 2015 401k financial data
Total unrealized appreciation/depreciation of assets	2015-12-31	$0
Total liabilities at end of year (benefit claims payable, operating payabales, acquisition indebtedness and other liabilities)	2015-12-31	$0
Total liabilities at beginning of year (benefit claims payable, operating payabales, acquisition indebtedness and other liabilities)	2015-12-31	$0
Total income from all sources (including contributions)	2015-12-31	$1,733,648
Total loss/gain on sale of assets	2015-12-31	$0
Total of all expenses incurred	2015-12-31	$437,522
Benefit payments and payments to participlants,beneficiaries,insurance carriers and others	2015-12-31	$424,037
Value of total corrective distributions	2015-12-31	$11,049
Total contributions o plan (from employers,participants, others, non cash contrinutions)	2015-12-31	$1,784,115
Value of total assets at end of year	2015-12-31	$20,721,536
Value of total assets at beginning of year	2015-12-31	$19,425,410
Total of administrative expenses incurred including professional, contract, advisory and management fees	2015-12-31	$2,436
Total interest from all sources	2015-12-31	$23,505
Total dividends received (eg from common stock, registered investment company shares)	2015-12-31	$-73,972
Has a resolution to terminate the plan been adopted during the plan year or any prior plan year	2015-12-31	No
Total dividends received from registered investment company shares (eg mutual funds)	2015-12-31	$-73,972
Was this plan covered by a fidelity bond	2015-12-31	Yes
Value of fidelity bond cover	2015-12-31	$500,000
If this is an individual account plan, was there a blackout period	2015-12-31	No
Were there any nonexempt tranactions with any party-in-interest	2015-12-31	No
Contributions received from participants	2015-12-31	$721,559
Participant contributions at end of year	2015-12-31	$322,561
Participant contributions at beginning of year	2015-12-31	$323,665
Income. Received or receivable in cash from other sources (including rollovers)	2015-12-31	$77,064
Administrative expenses (other) incurred	2015-12-31	$0
Did the receive any noncash contributions whose value was neither redily determinable on an established market nor set by an independent third party appraiser	2015-12-31	No
Value of net income/loss	2015-12-31	$1,296,126
Value of net assets at end of year (total assets less liabilities)	2015-12-31	$20,721,536
Value of net assets at beginning of year (total assets less liabilities)	2015-12-31	$19,425,410
Did the plan have a loss casued by fraud or dishonesty (regardless whether reimbursed by fidelity bond)	2015-12-31	No
Were any loans by the plan or fixed income obligations due to the plan in default	2015-12-31	No
Were any leases to which the plan was party in default or uncollectible	2015-12-31	No
Value of interest in pooled separate accounts at end of year	2015-12-31	$19,278,713
Value of interest in pooled separate accounts at beginning of year	2015-12-31	$18,137,288
Interest on participant loans	2015-12-31	$15,403
Value of interest in common/collective trusts at end of year	2015-12-31	$1,120,262
Value of interest in common/collective trusts at beginning of year	2015-12-31	$964,457
Interest earned from interest bearing cash (including money market accounts and certificates of deposit)	2015-12-31	$8,102
Were any plan transactions or series of transactions in excess of 5% of the current value of the plan assets	2015-12-31	No
Was there a failure to transmit to the plan any participant contributions	2015-12-31	No
Has the plan failed to provide any benefit when due under the plan	2015-12-31	No
Contributions received in cash from employer	2015-12-31	$985,492
Benefit payments and payments to provide benefits directly to participlants or beneficiaries including direct rollovers	2015-12-31	$424,037
Contract administrator fees	2015-12-31	$2,436
Did the plan have assets held for investment	2015-12-31	Yes
Did the plan hold any assets whose current value was neither redily determinable on an established market nor set by an independent third party appraiser	2015-12-31	No
Were all the plan assets eitehr distributed to particpants/beneficiaries, transferred to another plan or brought under the control of the PBGC	2015-12-31	No
Accountant perfomed limited scope audit pursuant to 29 CFR 2520.103-8 and/or 103-12(d)	2015-12-31	Yes
Opinion of an independent qualified public accountant for this plan	2015-12-31	Disclaimer
Accountancy firm name	2015-12-31	YOUNG, OAKES, BROWN & CO., PC
Accountancy firm EIN	2015-12-31	251589048
2014 : VALUE DRUG COMPANY 401(K) PROFIT-SHARING PLAN 2014 401k financial data
Total unrealized appreciation/depreciation of assets	2014-12-31	$0
Total liabilities at end of year (benefit claims payable, operating payabales, acquisition indebtedness and other liabilities)	2014-12-31	$0
Total liabilities at beginning of year (benefit claims payable, operating payabales, acquisition indebtedness and other liabilities)	2014-12-31	$0
Total income from all sources (including contributions)	2014-12-31	$2,927,697
Total loss/gain on sale of assets	2014-12-31	$0
Total of all expenses incurred	2014-12-31	$1,656,374
Benefit payments and payments to participlants,beneficiaries,insurance carriers and others	2014-12-31	$1,652,434
Expenses. Certain deemed distributions of participant loans	2014-12-31	$907
Total contributions o plan (from employers,participants, others, non cash contrinutions)	2014-12-31	$1,545,469
Value of total assets at end of year	2014-12-31	$19,425,410
Value of total assets at beginning of year	2014-12-31	$18,154,087
Total of administrative expenses incurred including professional, contract, advisory and management fees	2014-12-31	$3,033
Total interest from all sources	2014-12-31	$25,738
Total dividends received (eg from common stock, registered investment company shares)	2014-12-31	$1,356,490
Has a resolution to terminate the plan been adopted during the plan year or any prior plan year	2014-12-31	No
Total dividends received from registered investment company shares (eg mutual funds)	2014-12-31	$1,356,490
Was this plan covered by a fidelity bond	2014-12-31	Yes
Value of fidelity bond cover	2014-12-31	$500,000
If this is an individual account plan, was there a blackout period	2014-12-31	No
Were there any nonexempt tranactions with any party-in-interest	2014-12-31	No
Contributions received from participants	2014-12-31	$617,868
Participant contributions at end of year	2014-12-31	$323,665
Participant contributions at beginning of year	2014-12-31	$320,874
Income. Received or receivable in cash from other sources (including rollovers)	2014-12-31	$103,355
Administrative expenses (other) incurred	2014-12-31	$3,033
Total non interest bearing cash at beginning of year	2014-12-31	$0
Did the receive any noncash contributions whose value was neither redily determinable on an established market nor set by an independent third party appraiser	2014-12-31	No
Value of net income/loss	2014-12-31	$1,271,323
Value of net assets at end of year (total assets less liabilities)	2014-12-31	$19,425,410
Value of net assets at beginning of year (total assets less liabilities)	2014-12-31	$18,154,087
Did the plan have a loss casued by fraud or dishonesty (regardless whether reimbursed by fidelity bond)	2014-12-31	No
Were any loans by the plan or fixed income obligations due to the plan in default	2014-12-31	No
Were any leases to which the plan was party in default or uncollectible	2014-12-31	No
Value of interest in pooled separate accounts at end of year	2014-12-31	$18,137,288
Value of interest in pooled separate accounts at beginning of year	2014-12-31	$17,185,539
Interest on participant loans	2014-12-31	$15,781
Interest earned on other investments	2014-12-31	$3,128
Value of interest in common/collective trusts at end of year	2014-12-31	$964,457
Value of interest in common/collective trusts at beginning of year	2014-12-31	$647,674
Interest-bearing cash (include money market accounts & certificates of deposit) at beginning of the Year	2014-12-31	$0
Value of interest bearing cash (including money market accounts and certificates of deposits) at beginning of year	2014-12-31	$0
Interest earned from interest bearing cash (including money market accounts and certificates of deposit)	2014-12-31	$6,829
Were any plan transactions or series of transactions in excess of 5% of the current value of the plan assets	2014-12-31	No
Was there a failure to transmit to the plan any participant contributions	2014-12-31	No
Has the plan failed to provide any benefit when due under the plan	2014-12-31	No
Contributions received in cash from employer	2014-12-31	$824,246
Benefit payments and payments to provide benefits directly to participlants or beneficiaries including direct rollovers	2014-12-31	$1,652,434
Did the plan have assets held for investment	2014-12-31	Yes
Did the plan hold any assets whose current value was neither redily determinable on an established market nor set by an independent third party appraiser	2014-12-31	No
Were all the plan assets eitehr distributed to particpants/beneficiaries, transferred to another plan or brought under the control of the PBGC	2014-12-31	No
Accountant perfomed limited scope audit pursuant to 29 CFR 2520.103-8 and/or 103-12(d)	2014-12-31	Yes
Opinion of an independent qualified public accountant for this plan	2014-12-31	Disclaimer
Accountancy firm name	2014-12-31	YOUNG, OAKES, BROWN & CO., PC
Accountancy firm EIN	2014-12-31	251589048
2013 : VALUE DRUG COMPANY 401(K) PROFIT-SHARING PLAN 2013 401k financial data
Unrealized appreciation/depreciation of other (non real estate) assets	2013-12-31	$0
Total unrealized appreciation/depreciation of assets	2013-12-31	$0
Total income from all sources (including contributions)	2013-12-31	$4,274,952
Total of all expenses incurred	2013-12-31	$697,193
Benefit payments and payments to participlants,beneficiaries,insurance carriers and others	2013-12-31	$674,798
Total contributions o plan (from employers,participants, others, non cash contrinutions)	2013-12-31	$1,362,197
Value of total assets at end of year	2013-12-31	$18,154,087
Value of total assets at beginning of year	2013-12-31	$14,576,328
Total of administrative expenses incurred including professional, contract, advisory and management fees	2013-12-31	$22,395
Total interest from all sources	2013-12-31	$31,312
Total dividends received (eg from common stock, registered investment company shares)	2013-12-31	$789,005
Has a resolution to terminate the plan been adopted during the plan year or any prior plan year	2013-12-31	No
Total dividends received from registered investment company shares (eg mutual funds)	2013-12-31	$789,005
Was this plan covered by a fidelity bond	2013-12-31	Yes
Value of fidelity bond cover	2013-12-31	$500,000
If this is an individual account plan, was there a blackout period	2013-12-31	Yes
Total value of distributions paid in property other than in cash, annuity contracts, or publicly traded employer securities	2013-12-31	$0
Were there any nonexempt tranactions with any party-in-interest	2013-12-31	No
Contributions received from participants	2013-12-31	$561,782
Participant contributions at end of year	2013-12-31	$320,874
Participant contributions at beginning of year	2013-12-31	$371,199
Income. Received or receivable in cash from other sources (including rollovers)	2013-12-31	$31,786
Administrative expenses (other) incurred	2013-12-31	$22,395
Total non interest bearing cash at end of year	2013-12-31	$0
Total non interest bearing cash at beginning of year	2013-12-31	$0
Did the receive any noncash contributions whose value was neither redily determinable on an established market nor set by an independent third party appraiser	2013-12-31	No
Value of net income/loss	2013-12-31	$3,577,759
Value of net assets at end of year (total assets less liabilities)	2013-12-31	$18,154,087
Value of net assets at beginning of year (total assets less liabilities)	2013-12-31	$14,576,328
Did the plan have a loss casued by fraud or dishonesty (regardless whether reimbursed by fidelity bond)	2013-12-31	No
Were any loans by the plan or fixed income obligations due to the plan in default	2013-12-31	No
Were any leases to which the plan was party in default or uncollectible	2013-12-31	No
Value of interest in pooled separate accounts at end of year	2013-12-31	$17,185,539
Interest on participant loans	2013-12-31	$18,938
Income. Interest from loans (other than to participants)	2013-12-31	$0
Interest earned on other investments	2013-12-31	$5,849
Income. Interest from US Government securities	2013-12-31	$0
Value of interest in common/collective trusts at end of year	2013-12-31	$647,674
Value of interest in common/collective trusts at beginning of year	2013-12-31	$13,689,266
Value of interest bearing cash (including money market accounts and certificates of deposits) at end of year	2013-12-31	$0
Interest-bearing cash (include money market accounts & certificates of deposit) at beginning of the Year	2013-12-31	$515,863
Value of interest bearing cash (including money market accounts and certificates of deposits) at beginning of year	2013-12-31	$515,863
Interest earned from interest bearing cash (including money market accounts and certificates of deposit)	2013-12-31	$6,525
Net investment gain/loss from registered investment companies (e.g. mutual funds)	2013-12-31	$2,092,438
Were any plan transactions or series of transactions in excess of 5% of the current value of the plan assets	2013-12-31	No
Was there a failure to transmit to the plan any participant contributions	2013-12-31	No
Has the plan failed to provide any benefit when due under the plan	2013-12-31	No
Contributions received in cash from employer	2013-12-31	$768,629
Employer contributions (assets) at beginning of year	2013-12-31	$0
Benefit payments and payments to provide benefits directly to participlants or beneficiaries including direct rollovers	2013-12-31	$674,798
Contract administrator fees	2013-12-31	$0
Was the provided the required notice or one of the exceptions to providing the black out period notice applied under 29 CFR 2520.101-3	2013-12-31	Yes
Did the plan have assets held for investment	2013-12-31	Yes
Did the plan hold any assets whose current value was neither redily determinable on an established market nor set by an independent third party appraiser	2013-12-31	No
Were all the plan assets eitehr distributed to particpants/beneficiaries, transferred to another plan or brought under the control of the PBGC	2013-12-31	No
Accountant perfomed limited scope audit pursuant to 29 CFR 2520.103-8 and/or 103-12(d)	2013-12-31	Yes
Opinion of an independent qualified public accountant for this plan	2013-12-31	Disclaimer
Accountancy firm name	2013-12-31	YOUNG, OAKES, BROWN & CO., PC
Accountancy firm EIN	2013-12-31	251589048
2012 : VALUE DRUG COMPANY 401(K) PROFIT-SHARING PLAN 2012 401k financial data
Total income from all sources	2012-12-31	$2,773,633
Expenses. Total of all expenses incurred	2012-12-31	$3,273,588
Benefits paid (including direct rollovers)	2012-12-31	$3,270,621
Total plan assets at end of year	2012-12-31	$14,576,328
Total plan assets at beginning of year	2012-12-31	$15,076,283
Value of fidelity bond covering the plan	2012-12-31	$1,000,000
Total contributions received or receivable from participants	2012-12-31	$453,126
Contributions received from other sources (not participants or employers)	2012-12-31	$8,064
Other income received	2012-12-31	$1,658,628
Net income (gross income less expenses)	2012-12-31	$-499,955
Net plan assets at end of year (total assets less liabilities)	2012-12-31	$14,576,328
Net plan assets at beginning of year (total assets less liabilities)	2012-12-31	$15,076,283
Assets. Value of participant loans	2012-12-31	$371,199
Total contributions received or receivable from employer(s)	2012-12-31	$653,815
Value of certain deemed distributions of participant loans	2012-12-31	$-563
Value of corrective distributions	2012-12-31	$705
Expenses. Administrative service providers (salaries,fees and commissions)	2012-12-31	$2,825
Total value of distributions paid in property other than in cash, annuity contracts, or publicly traded employer securities	2012-12-31	$0
2011 : VALUE DRUG COMPANY 401(K) PROFIT-SHARING PLAN 2011 401k financial data
Total income from all sources	2011-12-31	$1,188,216
Expenses. Total of all expenses incurred	2011-12-31	$31,550
Benefits paid (including direct rollovers)	2011-12-31	$29,332
Total plan assets at end of year	2011-12-31	$15,076,283
Total plan assets at beginning of year	2011-12-31	$13,919,617
Value of fidelity bond covering the plan	2011-12-31	$1,000,000
Total contributions received or receivable from participants	2011-12-31	$405,974
Contributions received from other sources (not participants or employers)	2011-12-31	$253,085
Other income received	2011-12-31	$-104,552
Net income (gross income less expenses)	2011-12-31	$1,156,666
Net plan assets at end of year (total assets less liabilities)	2011-12-31	$15,076,283
Net plan assets at beginning of year (total assets less liabilities)	2011-12-31	$13,919,617
Assets. Value of participant loans	2011-12-31	$284,840
Total contributions received or receivable from employer(s)	2011-12-31	$633,709
Value of certain deemed distributions of participant loans	2011-12-31	$856
Value of corrective distributions	2011-12-31	$373
Expenses. Administrative service providers (salaries,fees and commissions)	2011-12-31	$989
Total value of distributions paid in property other than in cash, annuity contracts, or publicly traded employer securities	2011-12-31	$0
2010 : VALUE DRUG COMPANY 401(K) PROFIT-SHARING PLAN 2010 401k financial data
Total income from all sources	2010-12-31	$2,484,543
Expenses. Total of all expenses incurred	2010-12-31	$65,587
Benefits paid (including direct rollovers)	2010-12-31	$53,693
Total plan assets at end of year	2010-12-31	$13,919,617
Total plan assets at beginning of year	2010-12-31	$11,500,661
Value of fidelity bond covering the plan	2010-12-31	$1,000,000
Total contributions received or receivable from participants	2010-12-31	$374,463
Other income received	2010-12-31	$1,524,200
Net income (gross income less expenses)	2010-12-31	$2,418,956
Net plan assets at end of year (total assets less liabilities)	2010-12-31	$13,919,617
Net plan assets at beginning of year (total assets less liabilities)	2010-12-31	$11,500,661
Assets. Value of participant loans	2010-12-31	$297,650
Total contributions received or receivable from employer(s)	2010-12-31	$585,880
Value of corrective distributions	2010-12-31	$10,466
Expenses. Administrative service providers (salaries,fees and commissions)	2010-12-31	$1,428
Total value of distributions paid in property other than in cash, annuity contracts, or publicly traded employer securities	2010-12-31	$0
2009 : VALUE DRUG COMPANY 401(K) PROFIT-SHARING PLAN 2009 401k financial data
Total value of distributions paid in property other than in cash, annuity contracts, or publicly traded employer securities	2009-12-31	$0

Form 5500 Responses for VALUE DRUG COMPANY 401(K) PROFIT-SHARING PLAN

2022: VALUE DRUG COMPANY 401(K) PROFIT-SHARING PLAN 2022 form 5500 responses
2022-01-01	Type of plan entity	Single employer plan
2022-01-01	Plan funding arrangement – Trust	Yes
2022-01-01	Plan benefit arrangement - Trust	Yes
2021: VALUE DRUG COMPANY 401(K) PROFIT-SHARING PLAN 2021 form 5500 responses
2021-01-01	Type of plan entity	Single employer plan
2021-01-01	Plan funding arrangement – Trust	Yes
2021-01-01	Plan benefit arrangement - Trust	Yes
2020: VALUE DRUG COMPANY 401(K) PROFIT-SHARING PLAN 2020 form 5500 responses
2020-01-01	Type of plan entity	Single employer plan
2020-01-01	Submission has been amended	No
2020-01-01	This submission is the final filing	No
2020-01-01	This return/report is a short plan year return/report (less than 12 months)	No
2020-01-01	Plan is a collectively bargained plan	No
2020-01-01	Plan funding arrangement – Insurance	Yes
2020-01-01	Plan funding arrangement – Trust	Yes
2020-01-01	Plan benefit arrangement – Insurance	Yes
2020-01-01	Plan benefit arrangement - Trust	Yes
2019: VALUE DRUG COMPANY 401(K) PROFIT-SHARING PLAN 2019 form 5500 responses
2019-01-01	Type of plan entity	Single employer plan
2019-01-01	Submission has been amended	No
2019-01-01	This submission is the final filing	No
2019-01-01	This return/report is a short plan year return/report (less than 12 months)	No
2019-01-01	Plan is a collectively bargained plan	No
2019-01-01	Plan funding arrangement – Insurance	Yes
2019-01-01	Plan funding arrangement – Trust	Yes
2019-01-01	Plan benefit arrangement – Insurance	Yes
2019-01-01	Plan benefit arrangement - Trust	Yes
2018: VALUE DRUG COMPANY 401(K) PROFIT-SHARING PLAN 2018 form 5500 responses
2018-01-01	Type of plan entity	Single employer plan
2018-01-01	Submission has been amended	No
2018-01-01	This submission is the final filing	No
2018-01-01	This return/report is a short plan year return/report (less than 12 months)	No
2018-01-01	Plan is a collectively bargained plan	No
2018-01-01	Plan funding arrangement – Insurance	Yes
2018-01-01	Plan funding arrangement – Trust	Yes
2018-01-01	Plan benefit arrangement – Insurance	Yes
2018-01-01	Plan benefit arrangement - Trust	Yes
2017: VALUE DRUG COMPANY 401(K) PROFIT-SHARING PLAN 2017 form 5500 responses
2017-01-01	Type of plan entity	Single employer plan
2017-01-01	Submission has been amended	No
2017-01-01	This submission is the final filing	No
2017-01-01	This return/report is a short plan year return/report (less than 12 months)	No
2017-01-01	Plan is a collectively bargained plan	No
2017-01-01	Plan funding arrangement – Insurance	Yes
2017-01-01	Plan funding arrangement – Trust	Yes
2017-01-01	Plan benefit arrangement – Insurance	Yes
2017-01-01	Plan benefit arrangement - Trust	Yes
2016: VALUE DRUG COMPANY 401(K) PROFIT-SHARING PLAN 2016 form 5500 responses
2016-01-01	Type of plan entity	Single employer plan
2016-01-01	Submission has been amended	No
2016-01-01	This submission is the final filing	No
2016-01-01	This return/report is a short plan year return/report (less than 12 months)	No
2016-01-01	Plan is a collectively bargained plan	No
2016-01-01	Plan funding arrangement – Insurance	Yes
2016-01-01	Plan funding arrangement – Trust	Yes
2016-01-01	Plan benefit arrangement – Insurance	Yes
2016-01-01	Plan benefit arrangement - Trust	Yes
2015: VALUE DRUG COMPANY 401(K) PROFIT-SHARING PLAN 2015 form 5500 responses
2015-01-01	Type of plan entity	Single employer plan
2015-01-01	Submission has been amended	No
2015-01-01	This submission is the final filing	No
2015-01-01	This return/report is a short plan year return/report (less than 12 months)	No
2015-01-01	Plan is a collectively bargained plan	No
2015-01-01	Plan funding arrangement – Insurance	Yes
2015-01-01	Plan funding arrangement – Trust	Yes
2015-01-01	Plan benefit arrangement – Insurance	Yes
2015-01-01	Plan benefit arrangement - Trust	Yes
2014: VALUE DRUG COMPANY 401(K) PROFIT-SHARING PLAN 2014 form 5500 responses
2014-01-01	Type of plan entity	Single employer plan
2014-01-01	Submission has been amended	No
2014-01-01	This submission is the final filing	No
2014-01-01	This return/report is a short plan year return/report (less than 12 months)	No
2014-01-01	Plan is a collectively bargained plan	No
2014-01-01	Plan funding arrangement – Insurance	Yes
2014-01-01	Plan funding arrangement – Trust	Yes
2014-01-01	Plan benefit arrangement – Insurance	Yes
2014-01-01	Plan benefit arrangement - Trust	Yes
2013: VALUE DRUG COMPANY 401(K) PROFIT-SHARING PLAN 2013 form 5500 responses
2013-01-01	Type of plan entity	Single employer plan
2013-01-01	Submission has been amended	Yes
2013-01-01	This submission is the final filing	No
2013-01-01	This return/report is a short plan year return/report (less than 12 months)	No
2013-01-01	Plan is a collectively bargained plan	No
2013-01-01	Plan funding arrangement – Insurance	Yes
2013-01-01	Plan funding arrangement – Trust	Yes
2013-01-01	Plan benefit arrangement – Insurance	Yes
2013-01-01	Plan benefit arrangement - Trust	Yes
2012: VALUE DRUG COMPANY 401(K) PROFIT-SHARING PLAN 2012 form 5500 responses
2012-01-01	Type of plan entity	Single employer plan
2012-01-01	Submission has been amended	No
2012-01-01	This submission is the final filing	No
2012-01-01	This return/report is a short plan year return/report (less than 12 months)	No
2012-01-01	Plan funding arrangement – Trust	Yes
2012-01-01	Plan benefit arrangement - Trust	Yes
2011: VALUE DRUG COMPANY 401(K) PROFIT-SHARING PLAN 2011 form 5500 responses
2011-01-01	Type of plan entity	Single employer plan
2011-01-01	Submission has been amended	No
2011-01-01	This submission is the final filing	No
2011-01-01	This return/report is a short plan year return/report (less than 12 months)	No
2011-01-01	Plan funding arrangement – Trust	Yes
2011-01-01	Plan benefit arrangement - Trust	Yes
2009: VALUE DRUG COMPANY 401(K) PROFIT-SHARING PLAN 2009 form 5500 responses
2009-01-01	Type of plan entity	Single employer plan
2009-01-01	Submission has been amended	Yes
2009-01-01	This submission is the final filing	No
2009-01-01	This return/report is a short plan year return/report (less than 12 months)	No
2009-01-01	Plan is a collectively bargained plan	No
2009-01-01	Plan funding arrangement – Trust	Yes
2009-01-01	Plan benefit arrangement - Trust	Yes

Insurance Providers Used on plan

TRANSAMERICA LIFE INSURANCE COMPANY (National Association of Insurance Commissioners NAIC id number: 86231 )

Policy contract number

804648-000

Policy instance

Insurance contract or identification number	804648-000
Number of Individuals Covered	0
Insurance policy start date	2020-01-01
Insurance policy end date	2020-10-16
Total amount of commissions paid to insurance broker	USD $0
Total amount of fees paid to insurance company	USD $12,150
Are there contracts with unallocated funds for contract types other than deposit administration, immediate participation guarantee or guaranteed investment?	Yes
Commission paid to Insurance Broker	USD $0
Amount paid for insurance broker fees	12150
Insurance broker organization code?	5

TRANSAMERICA LIFE INSURANCE COMPANY (National Association of Insurance Commissioners NAIC id number: 86231 )

Policy contract number

804648-000

Policy instance

Insurance contract or identification number	804648-000
Number of Individuals Covered	250
Insurance policy start date	2019-01-01
Insurance policy end date	2019-12-31
Total amount of commissions paid to insurance broker	USD $0
Total amount of fees paid to insurance company	USD $15,494
Are there contracts with unallocated funds for contract types other than deposit administration, immediate participation guarantee or guaranteed investment?	Yes
Did the insurance company fail to provide any information necessary to complete Schedule A of form 5500?	No
Commission paid to Insurance Broker	USD $0
Amount paid for insurance broker fees	15494
Insurance broker organization code?	5

TRANSAMERICA LIFE INSURANCE COMPANY (National Association of Insurance Commissioners NAIC id number: 86231 )

Policy contract number

804648-000

Policy instance

Insurance contract or identification number	804648-000
Number of Individuals Covered	244
Insurance policy start date	2018-01-01
Insurance policy end date	2018-12-31
Total amount of commissions paid to insurance broker	USD $0
Total amount of fees paid to insurance company	USD $14,715
Are there contracts with unallocated funds for contract types other than deposit administration, immediate participation guarantee or guaranteed investment?	Yes
Did the insurance company fail to provide any information necessary to complete Schedule A of form 5500?	No
Commission paid to Insurance Broker	USD $0
Amount paid for insurance broker fees	14715
Additional information about fees paid to insurance broker	ADMINISTRATIVE FEES
Insurance broker organization code?	5

TRANSAMERICA LIFE INSURANCE COMPANY (National Association of Insurance Commissioners NAIC id number: 86231 )

Policy contract number

804648-000

Policy instance

Insurance contract or identification number	804648-000
Insurance policy start date	2017-01-01
Insurance policy end date	2017-12-31
Total amount of commissions paid to insurance broker	USD $0
Total amount of fees paid to insurance company	USD $12,736
Are there contracts with unallocated funds for contract types other than deposit administration, immediate participation guarantee or guaranteed investment?	Yes
Did the insurance company fail to provide any information necessary to complete Schedule A of form 5500?	No
Amount paid for insurance broker fees	12736
Insurance broker organization code?	5
Insurance broker name	CAPITAL RETIREMENT PLAN SERVICES,

TRANSAMERICA LIFE INSURANCE COMPANY (National Association of Insurance Commissioners NAIC id number: 86231 )

Policy contract number

804648-000

Policy instance

Insurance contract or identification number	804648-000
Insurance policy start date	2015-01-01
Insurance policy end date	2015-12-31
Total amount of commissions paid to insurance broker	USD $0
Total amount of fees paid to insurance company	USD $9,891
Are there contracts with unallocated funds for contract types other than deposit administration, immediate participation guarantee or guaranteed investment?	Yes
Commission paid to Insurance Broker	USD $0
Amount paid for insurance broker fees	9891
Insurance broker organization code?	5
Insurance broker name	CAPITAL RETIREMENT PLAN SERVICES,

TRANSAMERICA LIFE INSURANCE COMPANY (National Association of Insurance Commissioners NAIC id number: 86231 )

Policy contract number

804648-000

Policy instance

Insurance contract or identification number	804648-000
Insurance policy start date	2014-01-01
Insurance policy end date	2014-12-31
Total amount of commissions paid to insurance broker	USD $0
Total amount of fees paid to insurance company	USD $9,203
Commission paid to Insurance Broker	USD $0
Amount paid for insurance broker fees	9203
Additional information about fees paid to insurance broker	0
Insurance broker organization code?	5
Insurance broker name	CAPITAL RETIREMENT PLAN SERVICES,

TRANSAMERICA LIFE INSURANCE COMPANY (National Association of Insurance Commissioners NAIC id number: 86231 )

Policy contract number

804648-000

Policy instance

Insurance contract or identification number	804648-000
Number of Individuals Covered	126
Insurance policy start date	2013-01-01
Insurance policy end date	2013-12-31
Total amount of commissions paid to insurance broker	USD $0
Total amount of fees paid to insurance company	USD $0
Did the insurance company fail to provide any information necessary to complete Schedule A of form 5500?	No

Potentially related plans

VALUE DRUG, LTD. DBA PHARMACARE 401(K) PROFIT SHARING PLAN [EIN = 990092861]

Was this data useful?

If you found the data here useful, PLEASE HELP US. We are a start-up and believe in making information freely available. By linking to us, posting on twitter, facebook and linkedin about us and generally spreading the word, you'll help us to grow. Our vision is to provide high quality data about the activities of all the companies in the world and where possible make it free to use and view. Finding and integrating data from thousands of data sources is time consuming and needs lots of effort. By simply spreading the word about us, you will help us. Please use the share buttons. It will only take a few seconds of your time. Thanks for helping

Information Disclaimer

The information provided on this website is not advice, endorsement or recommendation
The information published is supplied by third parties so we make no warranty on the accuracy, completeness etc. This information is provided "as-is". The information is subject to change as we obtain updates and corrections from the primary information sources.
You are free to use the information for your own personal research on the understanding to do so is at your own risk.

See full terms and conditions

Company Name:	VALUE DRUG COMPANY
Employer identification number (EIN):	231179140
NAIC Classification:	424210
NAIC Description:	Drugs and Druggists' Sundries Merchant Wholesalers